Wegovy was approved by the FDA to reduce the risk of major cardiovascular events in obese or overweight adults with established cardiovascular disease.
Wegovy has been shown to reduce the risk of major adverse cardiac events by 20%, cardiovascular death by 15%, and death from any cause by 19%.